Biohaven Ltd.’s BHV-7000, a selective Kv7.2/7.3 potassium channel activator, is in phase II/III development for the treatment of focal epilepsy, generalized epilepsy, bipolar disorder and major depressive disorder. The company recently presented findings from preclinical testing assessing the candidate’s potential for the treatment of comorbidities associated with epilepsy.